IDYA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
10.2M
+15.6%
8.9M
+35.0%
6.6M
-39.7%
10.9M
-94.8%
207.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
10.2M
+15.6%
8.9M
+35.0%
6.6M
-39.7%
10.9M
-94.8%
207.8M
Operating Expenses
147.9M
+12.8%
131.1M
+13.9%
115.1M
+9.2%
105.4M
+6.1%
99.4M
R&D
121.6M
+11.9%
108.7M
+13.5%
95.7M
+10.5%
86.6M
+4.3%
83.0M
SG&A
26.3M
+17.1%
22.5M
+15.9%
19.4M
+2.8%
18.8M
+15.0%
16.4M
Operating Income
-137632000
-12.5%
-122291000
-12.7%
-108544000
-14.8%
-94570000
-187.2%
108.5M
EBITDA
-137018000
-12.7%
-121603000
-12.7%
-107856000
-14.9%
-93849000
-186.0%
109.1M
Net Income
-125749000
-11.8%
-112452000
-14.1%
-98539000
-18.3%
-83273000
-169.8%
119.2M
EPS (Basic)
$-1.22
+0.0%
$-1.22
-9.9%
$-1.11
-18.1%
$-0.94
-169.6%
$1.35
EPS (Diluted)
$-1.22
+0.0%
$-1.22
-9.9%
$-1.11
-16.8%
$-0.95
-171.4%
$1.33
Shares (Diluted)
102.9M
+11.8%
92.1M
+3.8%
88.7M
+1.5%
87.4M
-2.5%
89.7M
IDEAYA Biosciences (IDYA) — Financials